Pill form chemo shows promise for older lung cancer patients in new trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria Inclusion Criteria: * Age 70-85 years, any gender * ECOG performance status 0-1 * Pathologically confirmed non-small cell lung cancer (NSCLC), clinical stage IIA-IIIB (8th edition AJCC) * No distant metastasis, deemed resectable with curative intent * Negative for sensitive driver mutations including EGFR, ALK, and ROS1 by molecular pathology * Adequate function of major organs, defined as: * Bone marrow: ANC ≥1.5×10⁹/L, platelet ≥100×10⁹/L, hemoglobin ≥9 g/dL * Liver function: total bilirubin ≤1.5×ULN; ALT, AST ≤2.5×ULN * Renal function: serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min; urine protein \< +; if +, 24-h urine protein \< 500 mg * Normal blood glucose or well-controlled diabetes * Pulmonary function: baseline FEV1 ≥2 L; if FEV1 \< 2 L, postoperative predicted FEV1 \> 800 mL confirmed by surgical evaluation * Cardiac function: no myocardial infarction, unstable angina, severe arrhythmia, or cardiac insufficiency within the past 1 year * Patients and families are fully informed and voluntarily provide written informed consent Exclusion Criteria: * Previous lobectomy, radiotherapy, or systemic antitumor therapy * Synchronous other malignancy with \<5 years of cure (except carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin) * History of active autoimmune disease or requirement for systemic immunosuppressive therapy * Active infection requiring systemic therapy, including active tuberculosis, HIV infection, chronic hepatitis B/C with active replication, or syphilis * Severe cardiac, hepatic, renal, or metabolic disease that cannot tolerate surgery or study treatment * Previous interstitial lung disease, drug-induced pneumonitis, or radiologic evidence of active interstitial lung disease * Uncontrolled massive pleural effusion or pericardial effusion * Major surgery, severe trauma, or other investigational drug therapy within 4 weeks * Recent vaccination with antitumor vaccines or live vaccines * Other conditions deemed inappropriate for enrollment or likely to affect trial outcomes by the investigator